Abstract
Phosphocitrate, a phosphorylated polycarboxylic acid ameliorates two early events in atherogenesis. When administered to rats on an atherosclerotic diet (112 μmol/kg body wt./day), it reduced monocyte adhesion to aortic endothelium from 34± 7 cells/HPF for untreated rats to 1 ± 1 cell/HPF, a value seen in normal, non-atherosclerotic rats. Transmission electron microscopy of aortic sections showed no evidence of subendothelial lipid accumulation in phosphocitrate-treated rats despite the high circulating plasma lipid levels. The mechanisms of action of phosphocitrate are unknown but the indications are that its influence may be mediated through its polyanionic chemical nature and/or its ability to modulate cellular calcium accumulation. In addition to its possible therapeutic value as and anti-calcifying and anti-atherogenic compound, phosphocitrate may prove useful as an experimental probe for studying the cellular basis of atherogenesis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
